Itonaga I, Sabokbar A, Murray D W, Athanasou N A
Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford.
Ann Rheum Dis. 2000 Jan;59(1):26-31. doi: 10.1136/ard.59.1.26.
Osteoprotegerin ligand (OPGL) is a newly discovered molecule, which is expressed by osteoblasts/bone stromal cells. This ligand and M-CSF are now known to be essential for osteoclast differentiation from marrow and circulating precursors. This study examined whether OPGL and its soluble receptor osteoprotegerin (OPG), influenced osteoclast formation from human arthroplasty derived macrophages, to determine if the effects of OPGL and OPG on these cells could contribute to the osteolysis of aseptic loosening.
OPGL (+/- dexamethasone/M-CSF) was added to cultures of macrophages isolated from the pseudomembrane of loosened hip arthroplasties incubated on glass coverslips and dentine slices. OPG was added to cocultures of arthroplasty derived macrophages and UMR106 osteoblast-like cells. Osteoclast differentiation in long term cultures was assessed by expression of macrophage (CD14) and osteoclast markers (tartrate resistant acid phosphatase (TRAP), vitronectin receptor (VNR) and lacunar resorption).
In the absence of osteoblastic cells, the addition of OPGL alone was sufficient to induce differentiation of macrophages (CD14(+), TRAP(-), VNR(-)) into TRAP(+) and VNR(+) multinucleated cells, capable of extensive lacunar resorption. OPG was found to inhibit osteoclast formation by arthroplasty macrophages in a dose dependent manner. OPG (100 ng/ml) more than halved the formation of TRAP(+) and VNR(+) cells and the extent of lacunar resorption in co-cultures of UMR106 cells and arthroplasty macrophages.
This study has shown that macrophages, isolated from the pseudomembrane surrounding loose arthroplasty components, are capable of differentiating into osteoclastic bone resorbing cells and that OPGL is required for this to occur. OPG inhibits this process, most probably by interrupting the cell-cell interaction between osteoblasts and mononuclear phagocyte osteoclast precursors present in the pseudomembrane.
骨保护素配体(OPGL)是一种新发现的分子,由成骨细胞/骨基质细胞表达。现已知道该配体和巨噬细胞集落刺激因子(M-CSF)对于破骨细胞从骨髓和循环前体细胞的分化至关重要。本研究检测OPGL及其可溶性受体骨保护素(OPG)是否影响源自人工关节置换术的巨噬细胞形成破骨细胞,以确定OPGL和OPG对这些细胞的作用是否会导致无菌性松动的骨溶解。
将OPGL(±地塞米松/M-CSF)添加到从松动髋关节置换术假膜分离的巨噬细胞培养物中,这些巨噬细胞培养在玻璃盖玻片和牙本质切片上。将OPG添加到源自人工关节置换术的巨噬细胞与UMR106成骨样细胞的共培养物中。通过表达巨噬细胞标志物(CD14)和破骨细胞标志物(抗酒石酸酸性磷酸酶(TRAP)、玻连蛋白受体(VNR))以及腔隙吸收来评估长期培养中的破骨细胞分化。
在没有成骨细胞的情况下,单独添加OPGL足以诱导巨噬细胞(CD14(+)、TRAP(-)、VNR(-))分化为TRAP(+)和VNR(+)的多核细胞,这些细胞能够进行广泛的腔隙吸收。发现OPG以剂量依赖性方式抑制人工关节置换术巨噬细胞形成破骨细胞。在UMR106细胞与人工关节置换术巨噬细胞的共培养物中,OPG(100 ng/ml)使TRAP(+)和VNR(+)细胞的形成以及腔隙吸收程度减少一半以上。
本研究表明,从松动人工关节置换组件周围假膜分离的巨噬细胞能够分化为破骨细胞性骨吸收细胞,且这一过程需要OPGL。OPG抑制这一过程,很可能是通过中断成骨细胞与假膜中存在的单核吞噬细胞破骨细胞前体之间的细胞间相互作用来实现的。